Email your legislators today and urge them to OPPOSE SB1767/HB1852. Our health, our families, and our freedom to choose healthcare are at stake.

This article analyzes the core dialectic inherent in mRNA technology: the tension between its potential to advance human welfare and the risk of its capture by

Moderna's mRNA-based seasonal flu vaccine worked better than conventional flu shots in a late-stage international trial of more than 40,000 adults aged 50 and older, researchers ​reported on Wednesday...

mRNA drugs might be able to protect against a huge range of viruses by turning on key parts of our innate defences against infection

Researchers have created the world's first mRNA-based vaccine against a deadly, antibiotic-resistant bacterium — and they did it using the platform developed for COVID-19 vaccines. Medical Express publishes...

<p>WASHINGTON, D.C. - The U.S. Department of Health and Human Services (HHS) has terminated a $766 million contract with Moderna for the development of an mRNA-based vaccine against bird flu, sparking...

Exclusive: Melbourne team demonstrates way to make the virus visible within white blood cells, paving the way to fully clear it from the body

This article analyzes the core dialectic inherent in mRNA technology: the tension between its potential to advance human welfare and the risk of its capture by

Researchers demonstrated that mRNA technology can temporarily reprogram the liver in older mice to produce essential immune factors, restoring the generation of new immune cells and enabling strong immune responses to effectively combat tumors. ...

https://medicinespatentpool.org/news-publications-post/who-and-mpp-launch-phase-2-0-of-the-mrna-technology-transfer-programme On 21 October 2025, the Government of Belgium, the Medicines Patent Pool and the World Health Organization co-hosted this high-level mRNA Technology Transfer Programme event in Brussels. Belgium has been a steadfast champion of equitable access to vaccines and has provided crucial political and financial support to the Programme since its inception. Belgium underscores its commitment to strengthening pandemic preparedness and supporting sustainable regional vaccine production by convening global leaders, funders, and partners in the historic Egmont Palace. This gathering will provide an opportunity not only to showcase the achievements of the Programme but also to highlight Belgium’s leadership in driving innovation and collaboration for global health security. The Programme has benefited from strong political and financial backing, mobilising $123 million in funding from diverse contributors, including #Belgium, #Canada, ELMA Foundation, the #European Commission, #France, #Germany, #Norway, SAMRC, and #South Africa. This funding has catalysed additional investments; for instance, in the AFRO region, every dollar contributed by the Programme has triggered an estimated $17 in additional investments from regional stakeholders and public health institutions.